GlassScriptPhysician profile
Jenine N Vecchio
NPI 1891844569
$2,430.04
in general payments reported to CMS, 2019-2025
20 companies · $96.04 in 2025
The $96.04 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $230 · 2021: $618 · 2022: $493 · 2023: $534 · 2024: $460 · 2025: $96.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,059.92 | 2020-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $225.48 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $177.68 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.80 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $142.05 | 2021 | |
| Pfizer INC. | $113.12 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $69.23 | 2020-2022 | |
| Dexcom, INC. | $58.85 | 2020-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $54.34 | 2022-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $53.36 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $50.10 | 2021-2022 | |
| Insulet Corporation | $45.37 | 2020-2025 | Omnipod |
| Cequr Corporation | $38.62 | 2023 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $31.92 | 2021-2022 | |
| Beta Bionics, INC. | $30.17 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $29.38 | 2022 | |
| Ibsa Pharma INC. | $28.12 | 2022-2023 | Tirosint, Licart |
| Medtronic, INC. | $22.85 | 2023 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $14.90 | 2021 | |
| Glaxosmithkline, LLC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenine Vecchio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.